Project Grant R21EB036105

Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $1.3M
Federal Grant Program
93.286
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,360,447.52 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from Sep 1, 2024 to Aug 31, 2027. The grant funds the development and evaluation of an inexpensive, lightweight "brain monitor" device using...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,117,458 Project Grant (CFDA 93.286) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop next-generation in-vivo diffusion MRI (dMRI) technologies. The project aims to overcome key technical challenges in achieving high-quality, motion-robust mesoscale-resolution dMRI and microstructure imaging within clinically feasible scan times. The proposed innovations include...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides $185,625 to The General Hospital Corporation (Massachusetts General Hospital) to develop a novel magnetic resonance imaging (MRI) technology. The project aims to address the challenge of flip angle inhomogeneity in high-field 7 Tesla MRI systems by introducing a...
This $1,806,252 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) aims to develop advanced MRI techniques to improve pediatric imaging for diagnosing inflammatory bowel disease (IBD). The key objectives are to: 1) Enable faster dynamic 2D imaging at higher spatial and temporal resolutions, 2) Develop free-breathing 3D...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB), through its Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded a $412,801 Project Grant (R01EB035091) to Brigham & Women's Hospital Inc. in Boston, MA to develop an abbreviated, yet enhanced, brain MRI protocol. The goal is to significantly reduce MRI exam duration (from 20-30 minutes to 8 minutes) while capturing quantitative and qualitative MRI...
This Project Grant award of $1,344,298 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to optimize the image quality of mobile photon-counting CT (PCCT) scanners for use in the neuro intensive care unit (ICU). The key products and services to be delivered include: Development of deep learning-based image reconstruction algorithms to reduce noise...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $534,141 to Boston Children's Hospital to develop and evaluate advanced functional MRI (fMRI) acquisition methods for pre-surgical mapping in pediatric epilepsy patients. The key objectives are to: 1) Develop a novel technology using free induction decay (FID) navigators to measure...
The federal Project Grant award with ID R01EB036945 was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The $588,880 grant awarded to the Children's Hospital Corporation (doing business as Boston Children's Hospital) aims to develop fast, robust, and accurate methods for reconstructing coherent 3D fetal brain volumes from 2D MRI slice stacks,...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $732,220 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Comprehensive Prospective Correction of Head Motion in Functional MRI." The project aims to develop acquisition, image reconstruction, and analysis software to measure,...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $408,400 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and assess a wearable magnetoencephalography (MEG) system for use in children with epilepsy. The project aims to design age-appropriate OPM-MEG helmets that can accommodate variable pediatric head sizes...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $1,336,000.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop rapid, motion-robust, and low-gadolinium MRI techniques for improved diagnosis and monitoring of pediatric brain tumors.

The key objectives are to: (I) Develop cutting-edge technologies for rapid, motion-robust, and quantitative MRI scans that reduce the need for sedation and mitigate long-term cognitive effects on children; and (II) Synthesize clinically desired full-dose post-contrast images from low-dose quantitative MRI data. The project aims to address unmet needs in pediatric brain tumor imaging by advancing MRI methods to enhance image quality, reduce sedation requirements, and minimize gadolinium exposure. The technologies will be rigorously evaluated on non-sedated pediatric patients and compared to standard post-contrast imaging. All developed techniques will be disseminated through Siemens Healthineers' software platforms to facilitate broader clinical adoption.

Generated 5/13/25, 2:05 AM